A phase II study of pegylated liposomal @entity632 for treatment of advanced XXXX .

@entity632 @entity1 @entity137 @entity409 @entity56 @entity1575 @entity157
BACKGROUND: Pegylated liposomal @entity632 has an enhanced efficacy and reduced @entity137 compared with free @entity632 . The efficacy and @entity137 of pegylated liposomal @entity632 was investigated in @entity1 with @entity157 . @entity1 AND METHODS: @entity1 with histologically confirmed, locally advanced or metastatic @entity157 and a Karnofsky index > 60% were included in this prospective single-arm study. Exclusion criteria were @entity1575 stage @entity1 -Pugh C, previous chemotherapy, or chemoembolization. Pegylated liposomal @entity632 was given in a dose of 30 mg/m2 every three weeks until progression of disease. After inclusion of five @entity1 the dose could be escalated to 40 mg/m2 in absence of @entity137 grade 3 and 4. RESULTS: Sixteen @entity1 were evaluable for response. No objective response was achieved. The median survival time was 140 days (95% confidence interval: 126-154 days). Treatment @entity137 grade > or = 3 comprised increased liver enzymes in @entity1 with preexisting grade 1 or 2 elevation (n = 6), hematologic @entity137 (n = 5), and @entity56 (n = 2). CONCLUSIONS: Pegylated liposomal @entity632 is not effective for treatment of advanced @entity157 . The favorable @entity137 profile was confirmed even in @entity1 with underlying @entity409 .
